Conformation-Selective PI3Kδ Inhibitor Roginolisib Shows Safety and Survival Signals in First-in-Human Cancer Trial
Conformation-Selective PI3Kδ Inhibitor Roginolisib Shows Safety and Survival Signals in First-in-Human Cancer Trial Bioengineer.org
1140 материалов по теме, собраны автоматически из проверенных источников
Conformation-Selective PI3Kδ Inhibitor Roginolisib Shows Safety and Survival Signals in First-in-Human Cancer Trial Bioengineer.org
Ask Mayo Clinic: Clinical trials aren't the only option for blood cancer patients PennLive.com
Experimental cancer vaccine extends survival in brain cancer trial but falls short of statistical significance Indian Pharma Post
ACS–Fanconi Cancer Foundation Discovery Boost Grant: Up to $297,000 for Fanconi Anemia-Associated Cancer Research Oncodaily
World Cancer Research Fund 2026–2027 Regular Grant Programme Oncodaily
Blood Cancer United Specialized Center of Research (SCOR) 2026–2027: Up to $5 Million for Collaborative Blood Cancer Research Oncodaily
Istvan Borbiro: Presenting Cancer Care Coordination Study at EONS19 in Madrid Oncodaily
Tejas Patil: What Is Holding Back Cancer Clinical Trial Enrollment? Oncodaily
Anthony Letai: The Science and Collaboration Behind Progress in RAS-Targeted Cancer Research Oncodaily
Mebendazole and Cancer: Myths, Facts, and What the Research Really Shows Oncodaily
Nanoparticle Citrus Flavonoid Shields Kidneys in Mice with Cancer, Study Finds Bioengineer.org
Solomon Rotimi: Building a Stronger Future for Cancer Research Across Africa Oncodaily
Don’t Wait Until the Last Line to Consider Clinical Trials Targeted Oncology
Новое исследование: стереотактическая радиохирургия помогает пациентам с раком легких почти вдвое увеличить продолжительность жизни. Vietnam.vn
9 Hepatobiliary Cancer Trials to Watch at ESMO 2026 Oncodaily